Fosinopril Sodium

CHEMBL3039596 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
585.6 g/mol
LogP
Phase
4

This sodium salt form of fosinopril is an ACE inhibitor used to lower high blood pressure and treat heart failure by reducing the production of angiotensin II, which narrows blood vessels. Unlike many other ACE inhibitors, it is eliminated through both the liver and kidneys, making dosing adjustments less critical in kidney impairment.

Khối lượng phân tử

585,6000 g/mol

TPSA

113,00 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+]

InChI

InChI=1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39-;/m1./s1

Molecular Formula

C30H45NNaO7P

HBD / HBA

- / 7

Liên kết có thể quay

15

Nguyên tử nặng

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This sodium salt form of fosinopril is an ACE inhibitor used to lower high blood pressure and treat heart failure by reducing the production of angiotensin II, which narrows blood vessels. Unlike many other ACE inhibitors, it is eliminated through both the liver and kidneys, making dosing adjustments less critical in kidney impairment.

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Yes, Fosinopril Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039596. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23681451. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.